ALK Abello AS Aktie - 4AJ0

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Premium

Current Price

20,74

Gebot

20,34

Fragen

20,44

Volumen

0,00

0,00 Tagesbereich 0,00

19,05 52-Wochen-Bereich 24,56

Handelsende

20,74

Handelsbeginn

Letzte Trade

Letzter Handelszeitpunkt

Durchschnittliches Volumen (3 Mio.)

212

Finanzvolumen

VWAP

Invitation to the presentation of ALK’s annual report 2024 on Wednesday, 19 February 2025

Invitation to the presentation of ALK’s annual report 2024 on Wednesday, 19 February 2025 ALK (ALKB:DC / OMX: ALK B / AKBLF) will publish its...

ALK’s house dust mite tablet (ACARIZAX®) now recommended by NICE for use in the UK health system

ALK’s house dust mite tablet (ACARIZAX®) now recommended by NICE for use in the UK health system ALK (ALKB:DC / OMX: ALK B / AKBLF) today...

ALK – Financial calendar for the 2025 financial year

ALK – Financial calendar for the 2025 financial year 2025 financial calendar for ALK (ALKB:DC / OMX: ALK B / AKBLF): 22 January...

Positive results advance peanut tablet to phase II development

Positive results advance peanut tablet to phase II development ALK’s peanut tablet shown to be safe and tolerable across multiple...

ACARIZAX® approved in Europe for treatment of young children

ACARIZAX® approved in Europe for treatment of young children ALK (ALKB:DC / OMX: ALK B) today announced that its European regulatory filing for...

ALK’s pivotal phase 3 trial in children published in reputable scientific journal

ALK’s pivotal phase 3 trial in children published in reputable scientific journal The reputable scientific journal, The Lancet Regional Health –...

Nine-month interim report (Q3) 2024 (unaudited)

Nine-month interim report (Q3) 2024 (unaudited) Company release No. 19/2024 ALK delivers 18% organic revenue growth and an operating profit margin...

ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)

ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis) ALK (ALKB:DC...

Invitation to the presentation of ALK’s results for the first nine months (Q3) 2024 on Thursday 14 November 2024

Invitation to the presentation of ALK’s results for the first nine months (Q3) 2024 on Thursday 14 November 2024 ALK (ALKB:DC / OMX: ALK B /...

Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff

Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff ALK (ALKB:DC / OMX: ALK B / AKBLF): In...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	-0.8	-3.71402042711	21.54	21.78	20.7	77	21.02861566	DE
4	0.64	3.18407960199	20.1	22.3	19.96	237	20.90280133	DE
12	-0.159999	-0.765545491174	20.899999	22.54	19.51	212	20.86720112	DE
26	-0.6	-2.81162136832	21.34	24.56	19.51	291	22.36114112	DE
52	0.06	0.290135396518	20.68	24.56	19.05	313	21.7036709	DE
156	0.06	0.290135396518	20.68	24.56	19.05	313	21.7036709	DE
260	0.06	0.290135396518	20.68	24.56	19.05	313	21.7036709	DE

4AJ0 - Frequently Asked Questions (FAQ)

What is the current ALK Abello AS share price?

The current share price of ALK Abello AS is 20,74 €

What is the 1 year trading range for ALK Abello AS share price?

ALK Abello AS has traded in the range of 19,05 € to 24,56 € during the past year

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
VBXVoltabox AG	3,17 € (40,89%)	117,48k
GKOGlycoMimetics Inc	0,3805 € (38,62%)	804
1ZY0Medaro Mining Corp	0,11 € (34,97%)	26,32k
UH7ATennant Minerals NL	0,012 € (33,33%)	50,08k
HRJ1Sienna Resources Inc	0,0294 € (32,43%)	7,09k
POTAPortofino Resources Inc	0,0028 € (-46,15%)	5k
E3O1Nexoptic Technology Corp	0,01 € (-35,48%)	32,98k
L7C2Windfall Geotek Inc	0,0055 € (-35,29%)	2,24k
FYBFormycon AG	32,85 € (-33,97%)	197,59k
7N1GT Resources Inc	0,013 € (-31,58%)	13,38k
TKAThyssenkrupp AG	5,322 € (13,96%)	1,51M
D7GNel ASA	0,205 € (2,50%)	1,3M
3CPXiaomi Corporation	5,528 € (2,28%)	825,13k
DMLSayona Mining Limited	0,014 € (6,06%)	711,75k
VODIVodafone Group plc	0,7948 € (-0,85%)	667,85k

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

ALK Abello AS (4AJ0)

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Wichtige Statistiken und Details

4AJ0 Neueste Nachrichten

Invitation to the presentation of ALK’s annual report 2024 on Wednesday, 19 February 2025

ALK’s house dust mite tablet (ACARIZAX®) now recommended by NICE for use in the UK health system

ALK – Financial calendar for the 2025 financial year

Positive results advance peanut tablet to phase II development

ACARIZAX® approved in Europe for treatment of young children

ALK’s pivotal phase 3 trial in children published in reputable scientific journal

Nine-month interim report (Q3) 2024 (unaudited)

ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)

Invitation to the presentation of ALK’s results for the first nine months (Q3) 2024 on Thursday 14 November 2024

Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff

4AJ0 - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

ALK Abello AS (4AJ0) Börsenkurse

ALK Abello AS (4AJ0)

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Wichtige Statistiken und Details

4AJ0 Neueste Nachrichten

Invitation to the presentation of ALK’s annual report 2024 on Wednesday, 19 February 2025

ALK’s house dust mite tablet (ACARIZAX®) now recommended by NICE for use in the UK health system

ALK – Financial calendar for the 2025 financial year

Positive results advance peanut tablet to phase II development

ACARIZAX® approved in Europe for treatment of young children

ALK’s pivotal phase 3 trial in children published in reputable scientific journal

Nine-month interim report (Q3) 2024 (unaudited)

ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)

Invitation to the presentation of ALK’s results for the first nine months (Q3) 2024 on Thursday 14 November 2024

Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff

4AJ0 - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen